Caxton Associates (New York)’s United Therapeutics UTHR Stock Holding History

Caxton Associates (New York)’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$495K	Sell	1,402 -3,284	-70%	-$1.21M	0.02%	332
2024 Q3	$1.68M	Sell	4,686 -4,666	-50%	-$1.58M	0.06%	158
2024 Q2	$2.98M	Buy	+9,352	New	+$2.48M	0.1%	103
2024 Q1	–	Sell	-30,000	Closed	-$6.6M	–	590
2023 Q4	$6.6M	Buy	30,000 +29,059	+3,088%	+$6.7M	0.34%	57
2023 Q3	$213K	Buy	+941	New	+$217K	0.03%	353
2020 Q3	–	Sell	-7,013	Closed	-$849K	–	521
2020 Q2	$849K	Buy	+7,013	New	+$789K	0.07%	77
2020 Q1	–	Sell	-4,541	Closed	-$400K	–	593
2019 Q4	$400K	Sell	4,541 -2,099	-32%	-$185K	0.05%	220
2019 Q3	$530K	Buy	+6,640	New	+$535K	0.11%	118
2017 Q3	–	Sell	-2,800	Closed	-$363K	–	629
2017 Q2	$363K	Buy	2,800 +600	+27%	+$74.8K	0.01%	421
2017 Q1	$298K	Buy	+2,200	New	+$333K	﹤0.01%	349

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Caxton Associates (New York)'s UTHR Position: Q4 2024 in Review

Caxton Associates (New York) reduced its United Therapeutics (UTHR) stake by 70% in Q4 2024, selling an estimated $1.21M and leaving 1,402 shares worth $495K. The position accounts for 0.02% of the portfolio, ranked #332.

Caxton Associates (New York) first reported a position in UTHR in Q1 2017 and has held it in 10 quarters since. The position peaked at $6.6M in Q4 2023. 673 funds tracked by Wall St. Rank hold UTHR as of Q4 2024.

Caxton Associates (New York) held 1,402 shares of United Therapeutics worth $495K as of Q4 2024.
Caxton Associates (New York) sold 3,284 United Therapeutics shares in Q4 2024, an estimated $1.21M.
United Therapeutics made up 0.02% of Caxton Associates (New York)'s portfolio in Q4 2024, its #332 holding.
Caxton Associates (New York) first reported a position in United Therapeutics in Q1 2017 and has held it in 10 quarters since.
Caxton Associates (New York)'s United Therapeutics position peaked at $6.6M in Q4 2023.
673 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.